LIDOCAINE ACCORD 1% lidocaine hydrochloride 20 mg/2 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 1% lidocaine hydrochloride 20 mg/2 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium chloride; water for injections - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 2% lidocaine hydrochloride 40 mg/2 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 2% lidocaine hydrochloride 40 mg/2 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 40 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 1% lidocaine hydrochloride 100 mg/10 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 1% lidocaine hydrochloride 100 mg/10 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; sodium chloride - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 1% lidocaine hydrochloride 50 mg/5 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 1% lidocaine hydrochloride 50 mg/5 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 2% lidocaine hydrochloride 200 mg/10 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 2% lidocaine hydrochloride 200 mg/10 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 2% lidocaine hydrochloride 400 mg/20 mL injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 2% lidocaine hydrochloride 400 mg/20 ml injection vial

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 400 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; hydrochloric acid - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

LIDOCAINE ACCORD 2% lidocaine hydrochloride 100 mg/5 mL injection ampoule Australija - engleski - Department of Health (Therapeutic Goods Administration)

lidocaine accord 2% lidocaine hydrochloride 100 mg/5 ml injection ampoule

accord healthcare pty ltd - lidocaine hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - lidocaine accord solutions are indicated for the production of local or regional anaesthesia by the following techniques: ? infiltration ? intravenous regional anaesthesia ? peripheral nerve block ? epidural block ? subarachnoid block

Sunitinib Accord Europska Unija - engleski - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastic agents - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance.metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults.pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Sitagliptin Accord Europska Unija - engleski - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (ppary) agonist (i.e. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Degarelix Accord Europska Unija - engleski - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatic neoplasms - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer.for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.